ACTIVE HALF-LIFE
2-4 days
CLASSIFICATION
Non-steroidal aromatase inhibitor
DOSAGE
2.5-5 mg/day
ACNE
None
WATER RETENTION
None
HBR
No
HEPATOTOXICITY
None
AROMATIZATION
None
MANUFACTURER
Deus Medical
LAB TEST
Refer to Document
WAREHOUSE
EU Warehouse 2
SUBSTANCE
Letrozole
Introducing FEMAMED 2.5 (Letrozole), a powerful non-steroidal aromatase inhibitor designed specifically for hormonal treatment in breast cancer cases. Estrogens, the female sex hormones, often play a crucial role in the progression of breast cancer. That's where FEMAMED 2.5 comes into play.
This innovative treatment effectively reduces estrogen levels in the body by targeting the aromatase enzyme responsible for its production. By doing so, FEMAMED 2.5 helps to slow down the growth of estrogen-dependent breast cancer, offering a vital option in the fight against this disease.